Evaluation of the Efficacy of Prophylactic Use of Voriconazole Against Invasive Pulmonary Aspergillosis Among Severe Fever With Thrombocytopenia Syndrome Patients in China
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Deyu Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Voriconazole, Invasive Pulmonary Aspergillosis, Severe Fever with Thrombocytopenia Syndrome, Antifungal Agents. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Severe fever with thrombocytopenia syndrome (SFTS) associated pulmonary aspergillosis (SAPA) is one of the most serious complications and is strongly associated with high mortality. This study aimed to evaluate the efficacy of voriconazole (VRZ) prophylaxis against SAPA. SFTS patients were stratified into the following groups for comparative analysis: (i) SAPA versus non‐SAPA groups; (ii) nonprevention versus prevention groups; (iii) control high‐risk (CHR) versus prophylactic high‐risk (PHR) groups. The clinical burden of SAPA was assessed by comparing clinical characteristics between SAPA and non‐SAPA patients. The efficacy of VRZ prophylaxis was evaluated by comparing SAPA incidence, ICU admission rates, and mortality between nonprevention and prevention groups, as well as between CHR and PHR groups. Among 96 SFTS patients, 35 (36.5%) developed SAPA. The SAPA group exhibited significantly longer mean hospitalization (16.5 ± 12.1 days vs. 8.0 ± 3.1 days; p < 0.001), higher ICU admission rates (40.0% vs. 3.3%; p < 0.001), and higher mortality (34.3% vs. 3.3%; p < 0.001) than the non‐SAPA group. Prophylactic VRZ significantly reduced SAPA incidence in both the prevention group (29.0% vs. nonprovention group: 50%; p = 0.041) and the PHR group (47.1% vs. CHR group: 82.4%; p = 0.016). Similarly, ICU admission and mortality rates were markedly lower in the prevention group (4.8% and 8.1%, respectively) versus the nonprovention group (38.2% and 26.5%, respectively), and in the PHR group (5.9% and 11.8%, respectively) versus the CHR group (58.8% and 35.3%, respectively). Prophylactic VRZ significantly reduced SAPA incidence, ICU admissions, and mortality, with no serious adverse events observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Infectious Diseases, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China.
ORCID-Profile: Lintao Sai
Zitieren
APA
Huang, D., Song, L., Zou, W., Wang, L., & Sai, L. (2025). Evaluation of the Efficacy of Prophylactic Use of Voriconazole Against Invasive Pulmonary Aspergillosis Among Severe Fever With Thrombocytopenia Syndrome Patients in China. Journal of Medical Virology. https://doi.org/10.1002/jmv.70500
Vancouver
Huang D, Song L, Zou W, Wang L, Sai L. Evaluation of the Efficacy of Prophylactic Use of Voriconazole Against Invasive Pulmonary Aspergillosis Among Severe Fever With Thrombocytopenia Syndrome Patients in China. Journal of Medical Virology. 2025. doi:10.1002/jmv.70500
BibTeX
@article{Huang2025,
author = {Huang, Deyu and Song, Li and Zou, Wenlu and Wang, Lili and Sai, Lintao},
title = {Evaluation of the Efficacy of Prophylactic Use of Voriconazole Against Invasive Pulmonary Aspergillosis Among Severe Fever With Thrombocytopenia Syndrome Patients in China},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70500}
}
EUVIMED